Table 2.
Univariate analysis of overall survival, local control and regional control
| Variable | Median (months) | P value |
|---|---|---|
| Overall survival | ||
| Gender (M vs F) | 9.9 vs 14.5 | .07 |
| Histology (NSCLC vs others) | 14.4 vs 13.5 | .44 |
| Brain metastases at initial diagnosis (yes vs no) | 9.6 vs 14.3 | .67 |
| Number of brain metastases (1 vs ≥2) | 14.5 vs 8.0 | .09 |
| Time from initial diagnosis to SRS (<2 vs ≥2 y) | 9.9 vs 11.5 | .19 |
| Extent of resection (gross total vs subtotal) | 14.4 vs 10.8 | .42 |
| Extracranial metastatic disease (yes vs no) | 7.4 vs 24.1 | <.01 |
| Local control | ||
| Histology (NSCLC vs others) | NR | .26 |
| Dose (≤16 Gy vs >16 Gy) | NR | .38 |
| Preresection tumor size (≤3 cm3 vs >3 cm3) | NR | .04 |
| Extent of resection (GTR vs STR) | NR | .27 |
| Treatment volume (≤14 cm3 vs >14cm3) | NR | .02 |
| Target margin (≤2 mm vs >2 mm) | NR | .14 |
| Target margin (≤3 mm vs >3 mm) | NR | .24 |
| Regional control | ||
| Gender (M vs F) | 12.4 vs 17.6 | .73 |
| Histology (NSCLC vs others) | 20.2 vs 10.1 | .37 |
| Brain metastases at initial diagnosis (yes vs no) | 12.5 vs 15.7 | .63 |
| Number of brain metastases (1 vs ≥2) | 19.3 vs 11.1 | .07 |
| Time from initial diagnosis to SRS (<2 vs >2 y) | NR vs 12.5 | .23 |
| Extracranial metastatic disease (yes vs no) | 10.0 vs 27.4 | .03 |
F, female; GTR, gross total resection; M, male; NR, not reached; NSCLC, non-small cell lung cancer; SRS, stereotactic radiosurgery; STR, subtotal resection.